A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease

Interventions

DRUG

ROC-101

Oral, daily administered Rho kinase inhibitor